Measuring outcomes in systemic lupus erythematosus clinical trials

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 11, Issue 4, 2011, Pages 455-468

  Strand, Vibeke ^a   Chu, Alvina D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

disease activity; flare; outcome measure; responder index; systemic lupus erythematosus

Indexed keywords

A 623; ABATACEPT; ABR 215757; AMG 557; ANTIINFLAMMATORY AGENT; ATACICEPT; BELIMUMAB; BLISIBIMOD; BORTEZOMIB; CNTO 136; CORTICOSTEROID; EPRATUZUMAB; FORIGERIMOD; LY 2127399; OCRELIZUMAB; PAQUINIMOD; PF 04236921; PLACEBO; RITUXIMAB; RONTALIZUMAB; SBI 087; SIFALIMUMAB; UNCLASSIFIED DRUG;

CLINICAL ASSESSMENT; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; EVIDENCE BASED PRACTICE; HUMAN; INSTRUMENT VALIDATION; OUTCOME ASSESSMENT; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; STRATEGIC PLANNING; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT PLANNING;

EVIDENCE-BASED MEDICINE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 80051729839     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.38     Document Type: Review

References (107)

1. Smolen JS, Strand V, Cardiel M et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J. Rheumatol. 26(2), 504-507 (1999). (Pubitemid 29066766)
2. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Outcome measures in rheumatology. Lupus 9(5), 322-327 (2000). (Pubitemid 30389032)
3. Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 55(10), 756-760 (1996). (Pubitemid 26354438)
4. Gladman DD, Goldsmith CH, Urowitz MB et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J. Rheumatol. 21(8), 1468-1471 (1994). (Pubitemid 24261530)
5. Gladman DD, Goldsmith CH, Urowitz MB et al. Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J. Rheumatol. 19(4), 608-611 (1992).
6. Hawker G, Gabriel S, Bombardier C, Goldsmith C, Caron D, Gladman D. A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. J. Rheumatol. 20(4), 657-660 (1993). (Pubitemid 23138854)
7. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 32(9), 1107-1118 (1989). (Pubitemid 19237865)
8. Fortin PR, Abrahamowicz M, Clarke AE et al. Do lupus disease activity measures detect clinically important change? J. Rheumatol. 27(6), 1421-1428 (2000 (Pubitemid 30354038)
9. Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J. Rheumatol. 27(3), 664-670 (2000). (Pubitemid 30151343)
10. Isenberg DA, Rahman A, Allen E et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 44(7), 902-906 (2005). (Pubitemid 41511186)
11. Yee CS, Farewell V, Isenberg DA et al. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) 48(6), 691-695 (2009).
12. Yee CS, Farewell V, Isenberg DA et al. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 56(12), 4113-4119 (2007). (Pubitemid 350262339)
13. Vitali C, Bencivelli W, Mosca M, Carrai P, Sereni M, Bombardieri S. Development of a clinical chart to compute different disease activity indices for systemic lupus erythematosus. J. Rheumatol. 26(2), 498-501 (1999). (Pubitemid 29066764)
14. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 35(6), 630-640 (1992).
15. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 29(2), 288-291 (2002). (Pubitemid 34118775)
16. Petri M, Kim MY, Kalunian KC et al. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med. 353(24), 2550-2558 (2005). (Pubitemid 41785892)
17. Buyon JP, Petri MA, Kim MY et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann. Intern. Med. 142(12 Pt 1), 953-962 (2005).
18. Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. Lupus 19(1), 49-51 (2011).
19. Touma Z, Urowitz MB, Ibanez D, Gladman DD. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus 20(1), 67-70 (2011).
20. Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in systemic lupus erythematosus. J. Rheumatol. 27(2), 377-379 (2000). (Pubitemid 30095467)
21. Petri M. Disease activity assessment in SLE: do we have the right instruments? Ann. Rheum. Dis. 66(Suppl. 3), III61-III64 (2007). (Pubitemid 350032637)
22. Ibanez D, Urowitz MB, Gladman DD. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J. Rheumatol. 30(9), 1977-1982 (2003). (Pubitemid 37075547)
23. Strand V. Issues in drug development in SLE: clinical trial design, outcome measures, and biomarkers. In:Dubois' Lupus Erythematosus. Wallace DJ, Hahn BH (Eds). Lippincott Williams & Wilkins, PA, USA (2007).
24. Yee CS, Farewell VT, Isenberg DA et al. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) 50(5), 982-988 (2011).
25. Touma Z, Gladman DD, Ibanez D, Urowitz MB. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J. Rheumatol. 38(2), 275-284 (2011).
26. Touma Z, Urowitz MB, Fortin PR et al. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50: a reliable index for measuring improvement in disease activity. J. Rheumatol. 38(5), 868-873 (2011).
27. Hay EM, Bacon PA, Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 86(7), 447-458 (1993). (Pubitemid 23223653)
28. Yee CS, Cresswell L, Farewell V et al. Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford) 49(9), 1665-1669 (2010).
29. Nived O, Sturfelt G, Liang MH, De Pablo P. The ACR nomenclature for CNS lupus revisited. Lupus 12(12), 872-876 (2003). (Pubitemid 38082080)
30. Cresswell L, Yee CS, Farewell V et al. Numerical scoring for the Classic BILAG index. Rheumatology (Oxford) 48(12), 1548-1552 (2009).
31. Yee CS, Isenberg DA, Prabu A et al. BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Ann. Rheum. Dis. 67(6), 873-876 (2008). (Pubitemid 351829391)
32. Pope J. The revised BILAG Index with numerical scoring in systemic lupus erythematosus: added value with some limitations. Rheumatology (Oxford) 49(9), 1616-1617 (2010).
33. Wallace DJ, Hobbs K, Houssiau F et al. Epratuzumab (anti-CD22 mAb targeting B-cells) provides clinically meaningful reductions in corticosteroid (cs) use with a favorable safety profile in patients with moderate/severe flaring SLE: results from randomized controlled trials (RCTs). Arthritis Rheum. 58, S571 (2008).
34. Wallace D, Kalunian K, Petri M et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a Phase IIB study. Ann. Rheum. Dis. 69(Suppl. 3), 558 (2010).
35. Kalunian K, Wallace D, Petri M et al. BILAG-measured improvement in moderately and severely affected body systems in patients with systemic lupus erythematosus (SLE) by epratuzumab: results from EMBLEM, a Phase IIB study. Ann. Rheum. Dis. 69(Suppl. 3), 553 (2010).
36. Petri M, Hobbs K, Gordon C et al. Clinically meaningful improvements with epratuzumab (anti-CD22 mAb targeting B-cells) in patients (pts) with moderate/severe SLE flares: results from two randomized controlled trials. Arthritis Rheum. 58, S571 (2008).
37. Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 10(6), 405-409 (2001). (Pubitemid 32578615)
38. Alarcon GS, Roseman J, Bartolucci AA et al. Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum. 41(7), 1173-1180 (1998). (Pubitemid 28313417)
39. Zhang J, Gonzalez LA, Roseman JM, Vila LM, Reveille JD, Alarcon GS. Predictors of the rate of change in disease activity over time in LUMINA, a multiethnic US cohort of patients with systemic lupus erythematosus: LUMINA LXX. Lupus 19(6), 727-733 (2010).
40. Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46(11), 2924-2927 (2002).
41. Petri MA, Mease PJ, Merrill JT et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 50(9), 2858-2868 (2004).
42. Vitali C, Bencivelli W, Isenberg DA et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin. Exp. Rheumatol. 10(5), 541-547 (1992).
43. Houssiau FA, D'Cruz D, Sangle S et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann. Rheum. Dis. 69(12), 2083-2089 (2010).
44. Ruperto N, Hanrahan L, Alarcon G et al. International consensus for a definition of disease flare in lupus. Lupus 20(5), 453-462 (2011).
45. Fortin PR, Ferland D, Clarke AE et al. Activity and damage predicts later flares in lupus. Arthritis Rheum. 40, S207 (1997).
46. Fortin PR, Ferland D, Moore AD. Rates and predictors of lupus flares. Arthritis Rheum. 41, S218 (1998).
47. Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) 42(11), 1372-1379 (2003). (Pubitemid 37407029)
48. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46(12), 3251-3258 (2002). (Pubitemid 35453534)
49. Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled Phase III trial. Arthritis Rheum. 58(8), 2470-2480 (2008).
50. Alarcon-Segovia D, Tumlin JA, Furie RA et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 48(2), 442-454 (2003). (Pubitemid 36278013)
51. Navarra SV, Guzman RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, Phase 3 trial. Lancet 377(9767), 721-731 (2011).
52. Van Vollenhoven RF, Zamani O, Wallace DJ et al. Belimumab, a BLyS-specific inhibitor, reduces disease activity and severe flares in seropositive SLE patients: BLISS-76 study. Ann. Rheum. Dis. 69(Suppl. 3), 74 (2010).
53. Isenberg DA, Allen E, Farewell V et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann. Rheum. Dis. 70(1), 54-59 (2011).
54. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N. Engl. J. Med. 334(13), 835-840 (1996). (Pubitemid 26099607)
55. Thumboo J, Strand V. Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann. Acad. Med. Singapore 36(2), 115-122 (2007). (Pubitemid 46640263)
56. Abu-Shakra M, Mader R, Langevitz P et al. Quality of life in systemic lupus erythematosus: a controlled study. J. Rheumatol. 26(2), 306-309 (1999). (Pubitemid 29066733)
57. Thumboo J, Fong KY, Chan SP et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J. Rheumatol. 27(6), 1414-1420 (2000). (Pubitemid 30354037)
58. Saba J, Quinet RJ, Davis WE et al. Inverse correlation of each functional status scale of the SF-36 with degree of disease activity in systemic lupus erythematosus (m-SLAM). Joint Bone Spine 70(5), 348-351 (2003). (Pubitemid 37243269)
59. Doria A, Rinaldi S, Ermani M et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology (Oxford) 43(12), 1580-1586 (2004). (Pubitemid 39642587)
60. Rinaldi S, Doria A, Salaffi F et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age. Rheumatology (Oxford) 43(12), 1574-1579 (2004). (Pubitemid 39642586)
61. Alarcon GS, McGwin G Jr, Uribe A et al. Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum. 51(3), 465-474 (2004). (Pubitemid 38725149)
62. Zhu TY, Tam LS, Lee VW, Lee KK, Li EK. Relationship between flare and health-related quality of life in patients with systemic lupus erythematosus. J. Rheumatol. 37(3), 568-573 (2010).
63. Thumboo J, Fong KY, Ng TP et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J. Rheumatol. 26(1), 97-102 (1999). (Pubitemid 29051403)
64. Strand V, Crawford B. Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Expert Rev. Pharmacoeconomics Outcomes Res. 5(3), 317-326 (2005). (Pubitemid 40894969)
65. Strand V, Aranow C, Cardiel MH et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 12(9), 677-686 (2003). (Pubitemid 37173664)
66. Strand V, Levy RA, Cervera R et al. Belimumab, a BLyS-specific inhibitor, improved fatigue and SF-36 physical and mental component summary scores in patients with SLE: BLISS-76 and -52 studies. Arthritis Rheum. 62, S773 (2010).
67. Hochberg MC, Sutton JD. Physical disability and psychosocial dysfunction in systemic lupus erythematosus. J. Rheumatol. 15(6), 959-964 (1988).
68. Gladman DD, Urowitz MB, Ong A, Gough J, MacKinnon A. A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE). Lupus 5(3), 190-195 (1996). (Pubitemid 26197477)
69. Colangelo KJ, Pope JE, Peschken C. The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36. J. Rheumatol. 36(10), 2231-2237 (2009).
70. Burckhardt CS, Archenholtz B, Bjelle A. Quality of life of women with systemic lupus erythematosus: a comparison with women with rheumatoid arthritis. J. Rheumatol. 20(6), 977-981 (1993 (Pubitemid 23203238)
71. McElhone K, Abbott J, Shelmerdine J et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum. 57(6), 972-979 (2007). (Pubitemid 47237322)
72. McElhone K, Castelino M, Abbott J et al. The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. J. Rheumatol. 37(11), 2273-2279 (2010).
73. Jolly M, Pickard AS, Wilke C et al. Lupus-specific health outcome measure for US patients: the LupusQoL-US version. Ann. Rheum. Dis. 69(1), 29-33 (2010).
74. Doward LC, McKenna SP, Whalley D et al. The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann. Rheum. Dis. 68(2), 196-200 (2009).
75. Leong KP, Kong KO, Thong BY et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology (Oxford) 44(10), 1267-1276 (2005). (Pubitemid 41487960)
76. Jolly M, Pickard AS, Fogg L et al. U.S. patient derived lupus-specific patient reported outcome measure (Lupus-PRO): validity and reliability. Arthritis Rheum. 58, S805 (2008).
77. Furie RA, Petri MA, Wallace DJ et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 61(9), 1143-1151 (2009).
78. Wallace DJ, Stohl W, Furie RA et al. A Phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61(9), 1168-1178 (2009).
79. Strand V. Patients with active systemic lupus erythematosus (SLE) treated with belimumab improve heath-related quality of life (HRQOL) in a randomized controlled trial (RCT). Arthritis Rheum. 54, S277 (2006).
80. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J. Rheumatol. 26(2), 490-497 (1999). (Pubitemid 29066763)
81. Wekking EM. Psychiatric symptoms in systemic lupus erythematosus: an update. Psychosom. Med. 55(2), 219-228 (1993). (Pubitemid 23093013)
82. Strand V, Gordon C, Kalunian K et al. Meaningful improvements in health-related quality of life (HRQoL) with epratuzumab (anti-CD22 mAb targeting B-cells) in patients (pts) with SLE with high disease activity: results from 2 randomized controlled trials (RCTs). Arthritis Rheum. 58, S570 (2008).
83. Petri MA, Lahita RG, Van Vollenhoven RF et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 46(7), 1820-1829 (2002). (Pubitemid 34774514)
84. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr. Opin. Rheumatol. 13(5), 345-351 (2001). (Pubitemid 32929862)
85. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 39(3), 363-369 (1996). (Pubitemid 26085211)
86. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br. J. Rheumatol. 35(3), 248-254 (1996).
87. Gladman DD, Goldsmith CH, Urowitz MB et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus international comparison. J. Rheumatol. 27(2), 373-376 (2000). (Pubitemid 30095466)
88. Gladman DD, Urowitz MB, Goldsmith CH et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 40(5), 809-813 (1997). (Pubitemid 27199995)
89. Schiffenbauer J, Simon LS. Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? Lupus 13(5), 398-405 (2004). (Pubitemid 38788503)
90. Mease PJ, Ginzler EM, Gluck OS et al. Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy. J. Rheumatol. 32(4), 616-621 (2005). (Pubitemid 40524691)
91. Petri M, Barr SG, Buyon J, Davis J, Ginzler E, Kalunian K. RIFLE: responder index for lupus erythematosus. Arthritis Rheum. 43, S244 (2000).
92. Petri M, Brodsky RA, Jones RJ, Gladstone D, Fillius M, Magder LS. High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. Arthritis Rheum. 62(5), 1487-1493 (2010).
93. Bertsias G, Ioannidis JP, Boletis J et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann. Rheum. Dis. 67(2), 195-205 (2008). (Pubitemid 351183308)
94. Petri M, Kasitanon N, Lee SS et al. Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis Rheum. 58(6), 1784-1788 (2008). (Pubitemid 351847532)
95. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, Phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62(1), 222-233 (2010).
96. Merrill JT, Burgos-Vargas R, Westhovens R et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of SLE: results of a 12-month exploratory study. Arthritis Rheum. 62(10), 3077-3087 (2010).
97. Strand V. A novel means to demonstrate early efficacy of a product in systemic lupus erythematosus. Curr. Rheumatol. Rep. 9(6), 427-430 (2007). (Pubitemid 350305197)
98. Strand V. Lessons learned from clinical trials in SLE. Autoimmun. Rev. 6(4), 209-214 (2007). (Pubitemid 46274543)
99. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum. 50(11), 3418-3426 (2004).
100. Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. 62(1), 211-221 (2010
101. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N. Engl. J. Med. 353(24), 2539-2549 (2005 (Pubitemid 41785891)
102. US Department of Health and Human Services FDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for Industry: systemic lupus erythematosus - developing medical products for treatment (2010) www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/ UCM072063.pdf
103. US Department of Health and Human Services FDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for Industry: lupus nephritis caused by systemic lupus erythematosus - developing medical products for treatment (2010) www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/UCM216280.pdf
104. Corporate Translations website for LupusQoL translation www.corptransinc.com
105. US FDA News Release. FDA approves Benlysta to treat lupus (2011) www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm246489.htm
106. US FDA. Benlysta label for prescribing information (2011) www.accessdata.fda.gov/drugsatfda-docs/ label/2011/125370s0000lbl.pdf
107. ClinicalTrials.gov www.ClinicalTrials.gov